Transgenic mice that overexpress calcineurin develop cardiac hypertrophy, which can be prevented by treatment with immunosuppressive drugs that inhibit calcineurin.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A role for calcium in resistin transcriptional activation in diabetic hearts
Scientific Reports Open Access 23 October 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Molkentin, J.D. et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93, 215–228 (1998).
Sadoshima, J. & Izumo, S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu. Rev. Physiol. 59, 551–571 (1997).
Gruver, C.L., DeMayo, F., Goldstein, M.A. & Means, A.R. Targeted developmental overexpression of calmodulin induces proliferative and hypertrophic growth of cardiomyocytes in transgenic mice. Endocrinology 133, 376–388 (1993).
Morgan, J.P., Erny, R.E., Allen, P.D., Grossman, W. & Gwathmey, J.K. Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. Circulation 81, 21–32 (1990).
Takahashi, T. et al. Expression of dihydropyridine receptor (Ca2+ channel) and calsequestrin genes in the myocardium of patients with end-stage heart failure. J. Clin. Invest. 90, 927–935 (1992).
Herzig, T.C. et al. Angiotensin II type 1α receptor gene expression in the heart: AP-1 and GATA-4 participate in the response to pressure overload. Proc. Natl. Acad. Sci. USA 94, 7543–7548 (1997).
Rao, A., Luo, C. & Hogan, P.G. Transcription factors of the NF-AT family: Regulation and function. Annu. Rev. Immunol. 15, 707–747 (1997).
Schreiber, S.L. & Crabtree, G.R. The mechanism of action of cyclosporin A and FK506. Immunol. Today 13, 136–142 (1992).
Katz, A.M. Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure. N. Engl. J. Med. 322, 100–110 (1990).
Dolmetsch, R.E., Lewis, R.S., Goodnow, C.C. & Healy, J.I. Differential activation of transcription factors induced by Ca2+ response amplitude and duration. Nature 386, 855–858 (1997).
Mason, J.W. et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N. Engl. J. Med. 333, 269–275 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Izumo, S., Aoki, H. Calcineurin—the missing link in cardiac hypertrophy. Nat Med 4, 661–662 (1998). https://doi.org/10.1038/nm0698-661
Issue Date:
DOI: https://doi.org/10.1038/nm0698-661
This article is cited by
-
Dapagliflozin attenuates myocardial remodeling in hypertension by activating the circadian rhythm signaling pathway
Archives of Pharmacal Research (2023)
-
A role for calcium in resistin transcriptional activation in diabetic hearts
Scientific Reports (2018)
-
Activation of peroxisome proliferator-activated receptor gamma inhibits endothelin-1-induced cardiac hypertrophy via the calcineurin/NFAT signaling pathway
Molecular and Cellular Biochemistry (2008)
